logo

Natco Pharma Board Approves Rights Issue To Raise Up to Rs 1,279 Crore

Authored By PTI | Last Modified: Sep 25, 2026 04:00 PM IST

Stocks in News
NATCOPHARM
₹808
-0.10%
Natco Pharma Board Approves Rights Issue To Raise Up to Rs 1,279 Crore

Open Free Demat Account

By signing up I certify terms, conditions & privacy policy

New Delhi: Drug maker Natco Pharma on Friday said its board of directors has approved the issuance of equity shares through a rights issue to raise up to Rs 1,279.35 crore.

According to a regulatory filing, the company will issue up to 1,70,58,082 equity shares of face value of Rs 2 each at an issue price of Rs 750 per share to raise an amount not exceeding Rs 1,279.35 crore.

The rights issue has been approved at the entitlement ratio of 2 rights equity shares for every 21 fully paid-up equity shares held by eligible shareholders as on the record date, which has been fixed as October 1, 2026.

The rights issue is scheduled to open on October 12, 2026, and close on October 22, 2026. The on-market renunciation period will run from October 12 to October 16, 2026.

Upon full subscription, the company’s outstanding equity shares will rise from 17,91,09,870 shares to 19,61,67,952 shares post-issue.

The board also approved amendments to the company’s code of conduct to regulate, monitor, and report trading by designated persons during its meeting held on Friday, the filing added.

(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)

Disclaimer

The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.

Summarize with AI
Google GeminiChatGPTPerplexity AIAnthropic AIGrok AI
Desktop BannerMobile Banner

Invest Anytime, Anywhere

Get it on Google PlayGet it on App Store

Open Free Demat Account Online

By signing up I certify terms, conditions & privacy policy